OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company has enrolled the first patient into a pilot …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July …
Maxim’s healthcare analyst Jason Kolbert weighed in today with an optimistic view on OncoSec Medical Inc (NASDAQ:ONCS), after the company announced positive results from a …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced the appointment of David P. Meininger, PhD, MBA, to the newly created …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, promoted Sheela Mohan-Peterson, JD, MS, to Chief Legal and Compliance Officer, effective August …
In a research report released today, H.C.
In a research report released Tuesday, Maxim analyst Jason Kolbert maintained a Buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) with a $17.00 …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored …
Those that follow my biotech recommendations know that I look for undervalued small cap stocks with significant upside. Some may be momentum plays, …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Robert H. Pierce, MD, Chief Scientific Officer, will participate …